- Joined
- Mar 17, 2013
- Messages
- 1,337
Infliximab maintains durable response and facilitates catch-up growth in luminal paediatric Crohn’s disease. http://www.ncbi.nlm.nih.gov/pubmed/24865777
These data demonstrate sustained effectiveness of infliximab in children and adolescents with luminal CD. Durability of response is increased by concomitant immunomodulation. Clinical response is associated with enhanced linear growth, particularly when therapy is initiated early.
These data demonstrate sustained effectiveness of infliximab in children and adolescents with luminal CD. Durability of response is increased by concomitant immunomodulation. Clinical response is associated with enhanced linear growth, particularly when therapy is initiated early.
